Literature DB >> 31625143

Population-based study of morbidity risk associated with pathological complete response after chemoradiotherapy for rectal cancer.

F J van der Sluis1, A M Couwenberg2, G H de Bock3, M P W Intven2, O Reerink2, B L van Leeuwen4, H L van Westreenen1.   

Abstract

BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer may induce a pathological complete response (pCR) but increase surgical morbidity due to radiation-induced fibrosis. In this study the association between pCR and postoperative surgical morbidity was investigated.
METHODS: Patients in the Netherlands with rectal cancer who underwent nCRT followed by total mesorectal excision between 2009 and 2017 were included. Data were stratified into patients who underwent resection with creation of a primary anastomosis and those who had a permanent stoma procedure. The association between pCR and postoperative morbidity was investigated in univariable and multivariable logistic regression analyses.
RESULTS: pCR was observed in 976 (12·2 per cent) of 8003 patients. In 3472 patients who had a primary anastomosis, the presence of pCR was significantly associated with surgical complications (122 of 443 (27·5 per cent) versus 598 of 3029 (19·7 per cent) in those without pCR) and anastomotic leak (35 of 443 (7·9 per cent) versus 173 of 3029 (5·7 per cent) respectively). Multivariable analysis also showed associations between pCR and surgical complications (adjusted odds ratio (OR) 1·53, 95 per cent c.i. 1·22 to 1·92) and pCR and anastomotic leak (adjusted OR 1·41, 1·03 to 2·05). Of 4531 patients with a permanent stoma, surgical complications were observed in 120 (22·5 per cent) of 533 patients with a pCR, compared with 798 (20·0 per cent) of 3998 patients with no pCR (adjusted OR 1·17, 0·94 to 1·46).
CONCLUSION: Patients with a pCR in whom an anastomosis was created were at increased risk of developing an anastomotic leak.
© 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Year:  2019        PMID: 31625143     DOI: 10.1002/bjs.11324

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  Does Pathological Complete Response after Neoadjuvant Therapy Influence Postoperative Morbidity in Rectal Cancer after Transanal Total Mesorectal Excision?

Authors:  Martin Svoboda; Vladimír Procházka; Tomáš Grolich; Tomáš Pavlík; Monika Mazalová; Zdeněk Kala
Journal:  J Gastrointest Cancer       Date:  2022-05-07

2.  Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  Changlong Li; Zhen Guan; Yi Zhao; Tingting Sun; Zhongwu Li; Weihu Wang; Zhexuan Li; Lin Wang; Aiwen Wu
Journal:  Chin J Cancer Res       Date:  2022-08-30       Impact factor: 4.026

3.  A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer.

Authors:  Xiaolin Pang; Peiyi Xie; Li Yu; Haiyang Chen; Jian Zheng; Xiaochun Meng; Xiangbo Wan
Journal:  Br J Cancer       Date:  2022-04-06       Impact factor: 9.075

Review 4.  Effect of pathological complete response after neoadjuvant chemoradiotherapy on postoperative complications of rectal cancer: a systematic review and meta-analysis.

Authors:  J Yang; W Wang; Y Luo; S Huang; Z Fu
Journal:  Tech Coloproctol       Date:  2022-01-20       Impact factor: 3.781

Review 5.  MRI Evaluation of Complete Response of Locally Advanced Rectal Cancer After Neoadjuvant Therapy: Current Status and Future Trends.

Authors:  Qiaoyu Xu; Yanyan Xu; Hongliang Sun; Tao Jiang; Sheng Xie; Bee Yen Ooi; Yi Ding
Journal:  Cancer Manag Res       Date:  2021-06-01       Impact factor: 3.989

6.  Effects of Neoadjuvant Radiotherapy on Postoperative Complications in Rectal Cancer: A Meta-Analysis.

Authors:  Jianguo Yang; Yajun Luo; Tingting Tian; Peng Dong; Zhongxue Fu
Journal:  J Oncol       Date:  2022-01-05       Impact factor: 4.375

Review 7.  Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.

Authors:  Moying Li; Qiyun Xiao; Nachiyappan Venkatachalam; Ralf-Dieter Hofheinz; Marlon R Veldwijk; Carsten Herskind; Matthias P Ebert; Tianzuo Zhan
Journal:  Ther Adv Med Oncol       Date:  2022-02-21       Impact factor: 8.168

8.  Nuclear Receptor PXR Confers Irradiation Resistance by Promoting DNA Damage Response Through Stabilization of ATF3.

Authors:  Xiaxia Niu; Hongmei Cui; Xinsheng Gu; Ting Wu; Min Sun; Changlong Zhou; Mei Ma
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.